Melatonin as a potential therapeutic agent in psychiatric illness

Maria D. Maldonado, Russel J Reiter, Maria A. Pérez-San-Gregorio

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.

Original languageEnglish (US)
Pages (from-to)391-400
Number of pages10
JournalHuman Psychopharmacology
Volume24
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Melatonin
Psychiatry
Mental Disorders
Bipolar Disorder
Central Nervous System Agents
Anti-Anxiety Agents
Therapeutics
Hypnotics and Sedatives
Schizophrenia
Anti-Inflammatory Agents
Central Nervous System
Antioxidants
Brain
Pharmaceutical Preparations

Keywords

  • Immune function
  • Major psychiatric disorders
  • Melatonin
  • Neuroinflammation

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology
  • Pharmacology (medical)

Cite this

Melatonin as a potential therapeutic agent in psychiatric illness. / Maldonado, Maria D.; Reiter, Russel J; Pérez-San-Gregorio, Maria A.

In: Human Psychopharmacology, Vol. 24, No. 5, 2009, p. 391-400.

Research output: Contribution to journalArticle

Maldonado, Maria D. ; Reiter, Russel J ; Pérez-San-Gregorio, Maria A. / Melatonin as a potential therapeutic agent in psychiatric illness. In: Human Psychopharmacology. 2009 ; Vol. 24, No. 5. pp. 391-400.
@article{29b3ddf806a048fda51fd01a9daa12cd,
title = "Melatonin as a potential therapeutic agent in psychiatric illness",
abstract = "The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.",
keywords = "Immune function, Major psychiatric disorders, Melatonin, Neuroinflammation",
author = "Maldonado, {Maria D.} and Reiter, {Russel J} and P{\'e}rez-San-Gregorio, {Maria A.}",
year = "2009",
doi = "10.1002/hup.1032",
language = "English (US)",
volume = "24",
pages = "391--400",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Melatonin as a potential therapeutic agent in psychiatric illness

AU - Maldonado, Maria D.

AU - Reiter, Russel J

AU - Pérez-San-Gregorio, Maria A.

PY - 2009

Y1 - 2009

N2 - The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.

AB - The aim of this review was to summarize the potential use of melatonin in the treatment of mental disorders, specifically bipolar disorders, depression, and schizophrenia. To date, melatonin has been most commonly used in psychiatry because of its hypnotic, rhythm resynchronizing, and antioxidant actions. Here, we examine other properties of the melatonin including its anti-inflammatory, antinociceptive, anxiolytic, and drug detoxification actions as well as its protective effects against neural loss. The brain is an intricate sensory and motor organ which receives information from both the external and internal environments. It transduces information into complex chemical and electrical signals which are transmitted throughout the central nervous system (CNS) and the organism. The pathogenesis of mental disorders remains ambiguous and neuroinflammation has been proposed as a causative agent. We consider the potential contributions of melatonin as therapeutic agent in CNS and during neuroinflammation in mental disorders.

KW - Immune function

KW - Major psychiatric disorders

KW - Melatonin

KW - Neuroinflammation

UR - http://www.scopus.com/inward/record.url?scp=70149114138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70149114138&partnerID=8YFLogxK

U2 - 10.1002/hup.1032

DO - 10.1002/hup.1032

M3 - Article

C2 - 19551767

AN - SCOPUS:70149114138

VL - 24

SP - 391

EP - 400

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 5

ER -